ReviewKidney medicine
Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.
Review in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Widespread genetic testing controls inherited polycystic kidney disease while avoiding inbreeding in cats.BMC genomics · 2026Article
- Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.Molecular medicine (Cambridge, Mass.) · 2026Article
- Pregnancy in Autosomal Dominant Polycystic Kidney Disease: Maternal and Fetal Considerations: A Narrative Review.Journal of pregnancy · 2026Review
- Review
- Pilot study using a discrete mathematical approach for topological analysis and ssGSEA of gene expression in autosomal recessive polycystic kidney disease.Scientific reports · 2025Article
- Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.Hepatology (Baltimore, Md.) · 2025Article
- Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement.Radiology case reports · 2025Article
- The pathophysiological significance between autosomal dominant polycystic kidney disease and neutrophil gelatinase-associated lipocalin.Kidney research and clinical practice · 2025Article
- Prospects for gene therapy in polycystic kidney disease.Current opinion in nephrology and hypertension · 2025Review
- RETRACTED: Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease.Journal of personalized medicine · 2024Article
- Compliance with a Healthful Plant-Based Diet Is Associated with Kidney Function in Patients with Autosomal Dominant Polycystic Kidney Disease.Nutrients · 2024Article
- Glioneuronal tumor in an autosomal-dominant polycystic kidney disease patient: a case report and literature review.Annals of medicine and surgery (2012) · 2024Article
- Proteogenomics in Nephrology: A New Frontier in Nephrological Research.Current issues in molecular biology · 2024Review
- Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study.Clinical drug investigation · 2024Article
- Autosomal dominant polycystic kidney disease (ADPKD) with multiple complications: Management challenges.Narra J · 2024Article
- Prevalence and outcomes of polycystic kidney disease in African populations: A systematic review.World journal of nephrology · 2024Article
- Case Report: Autosomal dominant polycystic kidney disease and Wilms' tumor in infancy and childhood.Frontiers in pediatrics · 2024Article
- A new technique for the laparoscopic treatment of simple hepatic cysts.Surgery in practice and science · 2023Article
- Congenital Hepatic Fibrosis as an Early Sign of Presentation of ADPKD.Balkan journal of medical genetics : BJMG · 2023Article
- Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic kidney disease (PKD) is a multiorgan disorder resulting in fluid-filled cyst formation in the kidneys and other systems. The replacement of kidney parenchyma with an ever-increasing volume of cysts eventually leads to kidney failure. Recently, increased understanding of the pathophysiology of PKD and genetic advances have led to new approaches of treatment targeting physiologic pathways, which has been proven to slow the progression of certain types of the disease. We review the pathophysiologic patterns and recent advances in the clinical pharmacotherapy of autosomal dominant PKD. A multipronged approach with pharmacologic and nonpharmacologic treatments can be successfully used to slow down the rate of progression of autosomal dominant PKD to kidney failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.